Pacific Biosciences of California (PACB) Short Interest Up 23.8% in February

Pacific Biosciences of California (NASDAQ:PACB) saw a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 19,803,438 shares, an increase of 23.8% from the February 15th total of 15,999,916 shares. Based on an average daily volume of 2,116,544 shares, the days-to-cover ratio is currently 9.4 days. Approximately 14.5% of the company’s stock are sold short.

NASDAQ:PACB opened at $7.30 on Friday. Pacific Biosciences of California has a 1 year low of $2.02 and a 1 year high of $7.84. The company has a current ratio of 4.90, a quick ratio of 4.23 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $1.11 billion, a P/E ratio of -9.61 and a beta of 2.41.

Pacific Biosciences of California (NASDAQ:PACB) last posted its earnings results on Monday, February 11th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Pacific Biosciences of California had a negative net margin of 130.44% and a negative return on equity of 94.50%. The firm had revenue of $19.53 million during the quarter, compared to analyst estimates of $21.08 million. Research analysts forecast that Pacific Biosciences of California will post -0.56 EPS for the current year.

In other news, CEO Michael Hunkapiller sold 13,335 shares of the stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $7.19, for a total transaction of $95,878.65. Following the transaction, the chief executive officer now owns 2,388,750 shares in the company, valued at approximately $17,175,112.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Susan K. Barnes sold 11,987 shares of the stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $7.16, for a total transaction of $85,826.92. Following the transaction, the chief financial officer now owns 729,407 shares in the company, valued at approximately $5,222,554.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 39,486 shares of company stock worth $283,261. 13.40% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new position in Pacific Biosciences of California in the 4th quarter valued at $26,000. Hudock Capital Group LLC acquired a new stake in Pacific Biosciences of California in the 4th quarter worth $29,000. Clean Yield Group acquired a new stake in Pacific Biosciences of California in the 4th quarter worth $37,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Pacific Biosciences of California by 37.8% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,580 shares of the biotechnology company’s stock worth $71,000 after purchasing an additional 2,628 shares during the last quarter. Finally, Prudential Financial Inc. grew its position in Pacific Biosciences of California by 21.8% in the 4th quarter. Prudential Financial Inc. now owns 12,402 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 2,220 shares during the last quarter. Institutional investors and hedge funds own 67.70% of the company’s stock.

A number of research firms recently issued reports on PACB. BidaskClub lowered shares of Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine lowered shares of Pacific Biosciences of California from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 2nd. Finally, Cowen lowered shares of Pacific Biosciences of California from an “outperform” rating to a “market perform” rating in a research note on Friday, January 4th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $5.64.

ILLEGAL ACTIVITY WARNING: “Pacific Biosciences of California (PACB) Short Interest Up 23.8% in February” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://www.thelincolnianonline.com/2019/03/15/pacific-biosciences-of-california-pacb-short-interest-up-23-8-in-february.html.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time.

Read More: Technical Analysis

Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply